Systematic Verification of Bioanalytical Similarity Between a Biosimilar and a Reference Biotherapeutic: Committee Recommendations for the Development and Validation of a Single Ligand-Binding Assay to Support Pharmacokinetic Assessments

• Published in: The AAPS journal Vol. 16; no. 6; pp. 1149 - 1158
• Main Authors: Marini, Joseph C., Anderson, Michael, Cai, Xiao-Yan, Chappell, John, Coffey, Todd, Gouty, Dominique, Kasinath, Aparna, Koppenburg, Vera, Oldfield, Philip, Rebarchak, Shannon, Bowsher, Ronald R.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.11.2014
• Subjects: Biochemistry; Biological Assay - methods; Biological Assay - standards; Biomedical and Life Sciences; Biomedicine; Biosimilar Pharmaceuticals - pharmacokinetics; Biotechnology; Calibration; Drug Discovery; Ligands; Pharmacology/Toxicology; Pharmacy; Practice Guidelines as Topic; Radioligand Assay - methods; Radioligand Assay - standards; Reference Standards; Validation Studies as Topic; White Paper; biological product; ligand-binding assay; bioanalytical method validation; pharmacokinetic; biosimilar
• ISSN: 1550-7416; 1550-7416
• DOI: 10.1208/s12248-014-9669-5

For biosimilar drug development, it is critical to demonstrate similar physiochemical characteristics, efficacy, and safety of the biosimilar product compared to the reference product. Therefore, pharmacokinetic (PK) and immunogenicity (antidrug antibody, ADA) assays that allow for the demonstration of biosimilarity are critical. Under the auspices of the American Association of Pharmaceutical Scientists (AAPS) Ligand-Binding Assay Bioanalytical Focus Group (LBABFG), a Biosimilars Action Program Committee (APC) was formed in 2011. The goals of this Biosimilars APC were to provide a forum for in-depth discussions on issues surrounding the development and validation of PK and immunogenicity assays in support of biosimilar drug development and to make recommendations thereof. The Biosimilars APC’s recommendations for the development and validation of ligand-binding assays (LBAs) to support the PK assessments for biosimilar drug development are presented here. Analytical recommendations for the development and validation of LBAs to support immunogenicity assessments will be the subject of a separate white paper.